Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 27, 2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
read more
Wednesday, December 27, 2023
Jemincare, a leading pharmaceutical company from China, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer,...
read more
Wednesday, January 03, 2024
Ampersand Biomedicines has acquired AbCheck s.r.o., a technology company specializing in antibody discovery for challenging targets and formerly a wholly-owned subsidiary of Affimed GmbH. Ampersand, a multi-product platform company focused on ...
read more
Wednesday, January 03, 2024
Frontage Laboratories, Inc. has successfully completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera) through its wholly-owned subsidiary Frontage Europe S.r.l. Accelera, a Contract...
read more
Thursday, January 04, 2024
X-Chem, a provider of innovative solutions in early-stage drug discovery, announced executive management team changes aimed at expanding its position as a premium provider of integrated services to drug hunters.
read more
CordenPharma International and pHLIP, Inc. announced a strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.
read more
Tuesday, January 09, 2024
Premier Research, a global leader in clinical research, product development, and consulting, has joined forces with BioCentriq, a Contract Development and Manufacturing Organization (CDMO), in a strategic partnership aimed at transforming the pre-...
read more
Tuesday, January 09, 2024
Pluri Inc. has officially introduced a new business division, PluriCDMO™, dedicated to providing cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO). Leveraging over 20 years of development and ...
read more
Tuesday, January 09, 2024
Artelo Biosciences, Inc., a clinical-stage pharmaceutical company dedicated to modulating lipid-signaling pathways for developing treatments targeting cancer, pain, and neurological conditions, has chosen Worldwide Clinical Trials, a global contract ...
read more
Wednesday, January 10, 2024
Formerly known as Goodwin Biotechnology, GBI BioManufacturing has proudly announced the execution of its second Master Supply Agreement (MSA) to bring a radioimmunoconjugate product to the commercial market.
read more
Wednesday, January 10, 2024
In a strategic partnership, ValGenesis, Inc., a leader in digital validation, and GMP Pros, Inc., an engineering and technical solutions provider specializing in FDA-regulated manufacturing, join forces to introduce an innovative suite of digital ...
read more
Thursday, January 11, 2024
PCM Trials, a Denver, USA-based provider of mobile research nurses for decentralized clinical trials (DCTs), announced the acquisition of Clinical Trial Service (CTS).
read more
Tuesday, January 16, 2024
WuXi Biologics announced that its Research Service Unit has signed a research service agreement with BioNTech SE.
read more
Wednesday, January 17, 2024
Abzena has introduced the AbZelect™ and AbZelectPRO™ platforms for accelerating the generation of production cell lines used in the manufacturing of antibodies and recombinant proteins.
read more
Wednesday, January 17, 2024
The global pharmaceutical contract manufacturing market is anticipated to be worth USD 90 billion in 2023 and is expected to reach USD 140 billion by 2030. It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period ...
read more